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Reply
To the Editor:
We thank Drs Tutarel and Kielstein [1] for their interesting
remark concerning symmetrical dimethylarginine (SDMA) as a
possible biomarker for the detection of acute kidney injury (AKI)
after cardiac surgery. Postoperative AKI is certainly a vexing
complication of cardiac surgery, increasing mortality and mor-
bidity, predisposing patients to a longer hospitalization, and
requiring additional treatments [2]. Numerous studies have
attempted to determine AKI pathophysiology, and several pre-
ventive AKI strategies have been proposed along with clinical
and experimental studies suggesting that to achieve beneficial
effects, therapies to AKI severity need to be applied either before
or soon after renal injury [2]. Delayed AKI recognition inevitably
increases morbidity and mortality [2]. Therefore, the identifica-
tion of early and reliable AKI biomarkers is crucial [2]. Discern-
ing AKI etiologies, predicting the AKI severity, monitoring the
course of AKI, and the response to AKI interventions are all
essential features for a reliable AKI biomarker [2].
Symmetrical dimethylarginine is the structural isomer of the
asymmetric dimethylarginine, which has been reported as inde-
pendent risk factor for mortality in critically ill patients and amarker of progression of various chronic renal diseases [3–5].
Although plasma SDMA seems to correlate with established esti-
mates of glomerular filtration rate, at the moment, no data exist on
its correlation with AKI after cardiac surgery or for detecting it [5].
Available information refers to comparison of inflammatory and
oxidative stress after different types of cardiac surgery only [6–8].
We agree with Drs Tutarel and Kielstein [1] in considering
SDMA as a possible promising biomarker, but up to now, its
several lacks do not make it an early and recognized biomarker
for AKI after cardiac surgery. We hope that upcoming clinical
studies can definitively clarify SDMA usefulness in the cardiac
surgery setting.
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